Business
TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
Advances TriSalus’ Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer Expected to Advance Technology Development and Sales
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"\nAdvances TriSalus’ Platform Focused on Improving Outcomes for Patients with Liver and Pancreatic Cancer\n\n\nExpected to Advance Technology Development and Sales Growth\n\n\nAdvancing SD-101 Into Phase 2 Clinical Trial in Uveal Melanoma, Phase 1 Trial in Pancreatic Cancer and Continuing Clinical Trials in HCC and Cholangiocarcinoma\n\n\nProvides Cash Runway through Mid-2024 to Fund Key Milestones\n\n\nTriSalus’ Common Stock Expected to Begin Trading on the Nasdaq under Symbol \"TLSI\" on August 11, 2023\n\n\n DENVER & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--\nTriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech). TriSalus’ common stock and warrants are expected to commence trading on the Nasdaq Global Market under the ticker symbols “TLSI” and “TLSIW,” respectively, on August 11, 2023.\n\n\n“Completing our merger with MedTech marks an important milestone in our efforts to bring to market innovative approaches to treating liver and pancreatic tumors,” said Mary Szela, President and CEO of TriSalus. “Over the last several months we have advanced our device business and generated positive clinical data that supports the potential of our immunotherapeutic program. We are moving forward with the financial resources needed to grow our commercial organization and fund our key milestones through mid-2024. We believe that we are poised to create shareholder value as we continue our work to bring hope and improved treatments to the lives of patients. Finally, I want to especially thank our MTAC and TriSalus shareholders for trusting us to create value for them. I also want to thank our employees, interventional radiologists, and clinical investors and particularly our patients for their unwavering support that has been instrumental in helping us to achieve this milestone.”\n\n\n“We are excited to complete this merger with TriSalus and support the growth of its innovative devices and treatments,” said Chris Dewey, CEO of MedTech. “We believe that TriSalus has significant near and long-term value creation opportunities through its commercialization strategy and ...